Medical management
As noted earlier, many aortopathies are not known until pregnancy, and
medical management, α-Methyldopa or beta blocker can be utilised to slow
aortic growth and advised by the ESC38. Gersonyet al . contested this, having found no difference between beta
blocker use in a meta-analysis, and no change in
dilatation39. In addition, beta blockade has been
shown in several studies to have side effects, such as intrauterine
growth restriction and fetal bradycardia15. A study of
Celiprolol, however, had a decrease of arterial events (20%) in a
randomised control trial compared to control (50%), but this has not
been demonstrated in patients with aortic disease15.